BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavía M, Fernandez-Forcelledo JL, Cobo M, Fernández-Gil P, Ayestarán B, Sánchez B. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015;70:2376-2381. [PMID: 25855760 DOI: 10.1093/jac/dkv089] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter. 2016;21:382-388. [PMID: 26809022 DOI: 10.1111/hel.12294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
3 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
4 Georgopoulos SD, Papastergiou V, Martinez-Gonzalez B, Xirouchakis E, Familias I, Sgouras D, Mentis A, Karatapanis S. Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial. Ann Gastroenterol 2018;31:205-10. [PMID: 29507467 DOI: 10.20524/aog.2017.0221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Yurenev GL, Partzvania-vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Terapevticheskii arkhiv 2018;90:33-9. [DOI: 10.26442/terarkh201890833-39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1424] [Cited by in F6Publishing: 1169] [Article Influence: 284.8] [Reference Citation Analysis]
7 Macías-García F, Bastón-Rey I, de la Iglesia-García D, Calviño-Suárez C, Nieto-García L, Domínguez-Muñoz JE. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Helicobacter 2019;24:e12546. [PMID: 30346636 DOI: 10.1111/hel.12546] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
8 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261-87. [DOI: 10.7704/kjhugr.2020.0045] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
11 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. Med Clin (Barc) 2016;147:199-201. [PMID: 27374029 DOI: 10.1016/j.medcli.2016.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Chen MJ, Chen CC, Chen YN, Fang YJ, Lin JT, Wu MS, Liou JM;  Taiwan Gastrointestinal Disease Helicobacter Consortium. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113:1444-1457. [PMID: 30171216 DOI: 10.1038/s41395-018-0217-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
14 Campillo A, Amorena E, Ostiz M, Kutz M, Laiglesia M. Triple terapia 10 días con esomeprazol 40 mg/12 h vs. cuádruple concomitante sin bismuto como tratamiento de primera línea de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016;39:584-9. [DOI: 10.1016/j.gastrohep.2016.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Song ZQ, Liu J, Zhou LY. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin Med J (Engl). 2016;129:992-999. [PMID: 27064046 DOI: 10.4103/0366-6999.179803] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
16 Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, Song ZQ, Zou QH. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog 2017;109:156-61. [PMID: 28552806 DOI: 10.1016/j.micpath.2017.05.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
17 Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, Yang Y, Zhang D. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. European Journal of Gastroenterology & Hepatology 2021;33:775-86. [DOI: 10.1097/meg.0000000000001835] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
19 O'Connor A, Fischbach W, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2016. Helicobacter 2016;21 Suppl 1:55-61. [PMID: 27531541 DOI: 10.1111/hel.12342] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Hong J, Shu X, Liu D, Zhu Y, Xie C, Xie Y, Zhang K, Wang A, Xiong H, Zeng H. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71:2280-2285. [PMID: 27107097 DOI: 10.1093/jac/dkw118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
21 Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol 2016; 22(19): 4766-4775 [PMID: 27217708 DOI: 10.3748/wjg.v22.i19.4766] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]